Pfizer Inc. (NYSE:PFE) Shares Sold by Howe & Rusling Inc.

Howe & Rusling Inc. cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 16.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 52,415 shares of the biopharmaceutical company’s stock after selling 10,010 shares during the quarter. Howe & Rusling Inc.’s holdings in Pfizer were worth $1,509,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in PFE. Adage Capital Partners GP L.L.C. lifted its holdings in Pfizer by 40.5% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after purchasing an additional 1,365,295 shares in the last quarter. LifePlan Financial LLC purchased a new position in shares of Pfizer during the 4th quarter worth about $255,000. ETF Store Inc. lifted its holdings in shares of Pfizer by 12.0% during the 3rd quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock worth $214,000 after acquiring an additional 727 shares during the period. KLCM Advisors Inc. lifted its holdings in shares of Pfizer by 75.0% during the 4th quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock worth $5,004,000 after acquiring an additional 74,487 shares during the period. Finally, Farmers Trust Co. lifted its holdings in shares of Pfizer by 2.0% during the 4th quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company’s stock worth $6,503,000 after acquiring an additional 4,410 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Down 0.4 %

NYSE PFE opened at $27.08 on Thursday. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The company’s 50 day simple moving average is $26.87 and its 200 day simple moving average is $28.25. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $40.37. The company has a market capitalization of $153.34 billion, a P/E ratio of 75.47, a PEG ratio of 1.15 and a beta of 0.63.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same period in the previous year, the firm earned $1.14 EPS. The business’s revenue for the quarter was down 41.3% on a year-over-year basis. Equities research analysts expect that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be issued a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.20%. Pfizer’s dividend payout ratio is currently 466.67%.

Analysts Set New Price Targets

Several research firms recently commented on PFE. Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Finally, TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research report on Thursday, January 4th. Eleven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.